22:01 , Jun 17, 2019 |  BC Extra  |  Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout. HBM Healthcare Investments led the financing with participation from fellow...
23:09 , May 8, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
05:31 , May 2, 2019 |  BC Extra  |  Company News

AstraZeneca adds oncolytic virus option through Transgene deal

AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene. On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five...
19:11 , Apr 25, 2019 |  BC Week In Review  |  Clinical News

Viela publishes Phase Ib data for CD40L antagonist in RA

Viela said the highest two doses of VIB4920 (formerly MEDI4920) significantly reduced disease activity in a Phase Ib trial to treat rheumatoid arthritis. Data were published in Science Translational Medicine . Viela first reported data...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
23:16 , Apr 16, 2019 |  BC Extra  |  Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
19:24 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

MedImmune's bispecific mAb for Pseudomonas-related ocular keratitis

DISEASE CATEGORY: Infectious disease INDICATION: Pseudomonas Mouse studies suggest MEDI3902, a bispecific mAb against P. aeruginosa Psl and PcrV, could help treat ocular keratitis caused by P. aeruginosa infection. In a mouse model of bacterial...
03:13 , Mar 29, 2019 |  BC Extra  |  Company News

Daiichi gets $1.35B up front from AZ in antibody-drug conjugate deal

AstraZeneca will pay Daiichi Sankyo $1.35 billion up front to bolster one of the four platforms of its oncology unit, ADCs. Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Friday that they...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...